{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:58:06Z","timestamp":1762001886132,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40257-020-00511-5","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T11:03:20Z","timestamp":1584011000000},"page":"303-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oral Spironolactone for Acne Vulgaris in Adult Females: An Update of the Literature"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3729-7664","authenticated-orcid":false,"given":"Ruth A.","family":"Barker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison M.","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"511_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","volume":"18","author":"AM Layton","year":"2017","unstructured":"Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, Van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18:169\u201391.","journal-title":"Am J Clin Dermatol."},{"issue":"2\u20133","key":"511_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000471799","volume":"233","author":"R Grandhi","year":"2017","unstructured":"Grandhi R, Alikhan A. Spironolactone for the treatment of acne: a 4-year retrospective study. Dermatology. 2017;233(2\u20133):141\u20134.","journal-title":"Dermatology."},{"issue":"5","key":"511_CR3","first-page":"2","volume":"29","author":"H Rehman","year":"2018","unstructured":"Rehman H, Sarwar U, Majeed MM, Bokhari MA. Treatment of post adolescent female acne with spironolactone and low dose Isotretinoin. Med Forum Mon. 2018;29(5):2\u20136 (ISSN 1029385X).","journal-title":"Med Forum Mon."},{"issue":"2","key":"511_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijwd.2016.12.002","volume":"3","author":"JW Charny","year":"2017","unstructured":"Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol. 2017;3(2):111\u20135.","journal-title":"Int J Womens Dermatol."},{"issue":"4","key":"511_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1684\/ejd.2017.3062","volume":"27","author":"A Isvy-Joubert","year":"2017","unstructured":"Isvy-Joubert A, Nguyen JM, Gaultier A, Saint-Jean M, Le Moigne M, Boisrobert E, et al. Adult female acne treated with spironolactone: a retrospective data review of 70 cases. Eur J Dermatol. 2017;27(4):393\u20138.","journal-title":"Eur J Dermatol."},{"issue":"3","key":"511_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijwd.2019.04.024","volume":"5","author":"RM Thiede","year":"2019","unstructured":"Thiede RM, Rastogi S, Nardone B, Sadowsky LM, Rangel SM, West DP, et al. Hyperkalemia in women with acne exposed to oral spironolactone: a retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program. Int J Womens Dermatol. 2019;5(3):155\u20137.","journal-title":"Int J Womens Dermatol."},{"key":"511_CR7","first-page":"74","volume":"177","author":"N Elshimy","year":"2017","unstructured":"Elshimy N, Whitehouse H, Blakeway E, Eady A, Layton A. Is it necessary to monitor serum electrolytes in healthy women using spironolactone for the treatment of acne? Br J Dermatol. 2017;177:74\u20135.","journal-title":"Br J Dermatol."},{"issue":"6","key":"511_CR8","first-page":"632","volume":"17","author":"JS Barbieri","year":"2018","unstructured":"Barbieri JS, Choi JK, Mitra N, Margolis DJ. Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010\u20132016. J Drugs Dermatol. 2018;17(6):632\u20138.","journal-title":"J Drugs Dermatol."},{"issue":"1","key":"511_CR9","first-page":"101","volume":"29","author":"M Sanai","year":"2019","unstructured":"Sanai M, Shaukat S, Ghias A, Asghar A, Nadeem M, Ahmed TJ. Efficacy and safety of spironolactone in moderate to severe acne in females. J Pakistan Assoc Dermatol. 2019;29(1):101\u20139.","journal-title":"J Pakistan Assoc Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00511-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-020-00511-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00511-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T01:03:01Z","timestamp":1615510981000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-020-00511-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00511-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"type":"print","value":"1175-0561"},{"type":"electronic","value":"1179-1888"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"12 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this letter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors received funding or payments of any type from the manufacturers of any of the products included in this letter. Ruth A. Barker, Christopher Wilcox and Alison M. Layton have no conflicts of interest that are directly relevant to the content of this letter.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}